Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent. This is a 13.63 percent decrease over sales of $1.262 million the same period last year.